-
肺癌是一种严重威胁人类生命健康的恶性肿瘤,在全球常见的癌症中,肺癌最为常见,亦是癌症患者病死的首要原因[1]。在我国,肺癌也位居城市人口恶性肿瘤病死原因的首位,其中85%~88%的肺癌为非小细胞肺癌(non-small cell lung cancer,NSCLC)[2]。男性吸烟、嗜烟可能与肺癌的高发病率和病死率密切相关。但值得关注的是,近年来不吸烟女性肺癌发病率逐年升高,而且病理类型均为肺腺癌。虽然肺癌的诊断和治疗取得了很大的进步,但是,仍有相当一部分患者因某些特殊情况无法明确组织病理学类型或者亚型。PET/CT作为一种无创性影像学检查技术,其常用显像剂18F-FDG可以从分子水平反映肿瘤细胞的代谢情况,其在肺癌诊治上的应用得到了广泛认可。近年来,有研究者探索了18F-FDG PET/CT代谢参数与NSCLC病理类型的关系。尽管目前相关报道不是很多,但结果却令人鼓舞。我们就18F-FDG PET/CT代谢参数与NSCLC病理类型相关性的研究进展进行综述。
18F-FDG PET/CT代谢参数与非小细胞肺癌病理类型相关性的研究进展
Research progress of correlation between 18F-FDG PET/CT metabolic parameters and pathological types of non-small cell lung cancer
-
摘要: 肺癌是一种严重威胁人类生命健康的恶性肿瘤,其病理类型影响着治疗方案的制定及患者的预后。虽然肺癌的诊断和治疗取得了很大的进步,但是,仍有相当一部分患者因某些特殊情况无法明确组织病理学类型或亚型。18F-氟脱氧葡萄糖(FDG) PET/CT作为一种新型无创的影像学检查技术,可以直观地反映肿瘤代谢程度,其代谢参数与非小细胞肺癌(NSCLC)病理类型具有一定的相关性。影像组学是一个发展中的学科,旨在从医学图像中提取自动化的定量成像特征,并能无创地预测肺癌的病理类型。笔者就18F-FDG PET/CT在预测NSCLC病理类型中的应用及进展进行综述。Abstract: Lung cancer is a malignant tumor that seriously threatens human life and health, and its pathological type affects the treatment plan and prognosis. Although great progress has been made in the diagnosis and treatment of lung cancer, there are still a considerable number of patients whose histopathological type or subtype cannot be defined due to some special circumstances. 18F-fluorodeoxyglucose (FDG) PET/CT, as a new non-invasive imaging technique, can directly reflect the degree of tumor metabolism, and its metabolic parameters have a certain correlation with the pathological types of non-small cell lung cancer (NSCLC). Radiomics is a developing discipline, which aims to obtain automated quantitative imaging functions from medical images and be able to predict the pathological type of lung cancer non-invasively. This paper reviews the application and progress of 18F-FDG PET/CT in predicting the pathological types of NSCLC.
-
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394−424. DOI: 10.3322/caac.21492. [2] 丁重阳, 郭喆, 孙晋, 等. 18F-FDG PET/CT预测周围型非小细胞肺癌小病灶隐匿性淋巴结转移的价值[J]. 中华核医学与分子影像杂志, 2018, 38(7): 493−494. DOI: 10.3760/cma.j.issn.2095-2848.2018.07.009.
Ding CY, Guo Z, Sun J, et al. Value of 18F-FDG PET/CT imaging to predict occult lymph node metastasis in small-sized peripheral non-small cell lung cancer[J]. Chin J Nucl Med Mol Imaging, 2018, 38(7): 493−494. DOI: 10.3760/cma.j.issn.2095-2848.2018.07.009.[3] Zheng M. Classification and pathology of lung cancer[J]. Surg Oncol Clin N Am, 2016, 25(3): 447−468. DOI: 10.1016/j.soc.2016.02.003. [4] Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American thoracicsociety/European respiratory society international multidisciplinary classification of lung adenocarcinoma[J]. J Thorac Oncol, 2011, 6(2): 244−285. DOI: 10.1097/JTO.0b013e318206a221. [5] Sun XY, Chen TX, Chang C, et al. SUVmax of 18FDG PET/CT predicts histological grade of lung adenocarcinoma[J]. Acad Radiol, 2020, 28(1): 49−57. DOI: 10.1016/j.acra.2020.01.030. [6] de Geus-Oei LF, van Krieken JHJM, Aliredjo RP, et al. Biological correlates of FDG uptake in non-small cell lung cancer[J]. Lung Cancer, 2007, 55(1): 79−87. DOI: 10.1016/j.lungcan.2006.08.018. [7] Kim DH, Jung JH, Son SH, et al. Prognostic significance of intratumoral metabolic heterogeneity on 18F-FDG PET/CT in pathological N0 non-small cell lung cancer[J]. Clin Nucl Med, 2015, 40(9): 708−714. DOI: 10.1097/RLU.0000000000000867. [8] Li MH, Sun Y, Liu YH, et al. Relationship between primary lesion FDG uptake and clinical stage at PET-CT for non-small cell lung cancer patients: an observation[J]. Lung Cancer, 2010, 68(3): 394−397. DOI: 10.1016/j.lungcan.2009.07.009. [9] Karam MB, Doroudinia A, Behzadi B, et al. Correlation of quantified metabolic activity in nonsmall cell lung cancer with tumor size and tumor pathological characteristics[J]. Medicine (Baltimore), 2018, 97(32): e11628. DOI: 10.1097/MD.0000000000011628. [10] 王少雁, 张建, 孙高峰, 等. 18F-FDG PET/CT最大标准摄取值联合HRCT在肺癌诊断中的价值和影响因素分析[J]. 中华核医学与分子影像杂志, 2013, 33(1): 29−33. DOI: 10.3760/cma.j.issn.2095-2848.2013.01.008.
Wang SY, Zhang J, Sun GF, et al. The maximum standardized uptake value of 18F-FDG PET/CT combined with the image features on high resolution CT for the diagnosis of lung cancer[J]. Chin J Nucl Med Mol Imaging, 2013, 33(1): 29−33. DOI: 10.3760/cma.j.issn.2095-2848.2013.01.008.[11] Meijer TWH, de Geus-Oei LF, Visser EP, et al. Tumor delineation and quantitative assessment of glucose metabolic rate within histologic subtypes of non-small cell lung cancer by using dynamic 18F fluorodeoxyglucose PET[J]. Radiology, 2017, 283(2): 547−559. DOI: 10.1148/radiol.2016160329. [12] Suárez-Piñera M, Belda-Sanchis J, Taus A, et al. FDG PET-CT SUVmax and IASLC/ATS/ERS histologic classification: a new profile of lung adenocarcinoma with prognostic value[J/OL]. Am J Nucl Med Mol Imaging, 2018, 8(2): 100−109[2020-09-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944825. [13] Kadota K, Colovos C, Suzuki K, et al. FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage Ⅰ lung adenocarcinoma[J]. Ann Surg Oncol, 2012, 19(11): 3598−3605. DOI: 10.1245/s10434-012-2414-3. [14] Shao XL, Niu R, Jiang ZX, et al. Role of PET/CT in management of early lung adenocarcinoma[J]. AJR Am J Roentgenol, 2020, 214(2): 437−445. DOI: 10.2214/AJR.19.21585. [15] 吕晓虹, 向阳, 刘宁, 等. PET/CT联合高分辨率CT对肺单发磨玻璃结节侵袭性的诊断价值[J]. 实用放射学杂志, 2020, 36(5): 722−726. DOI: 10.3969/j.issn.1002-1671.2020.05.009.
Lyu XH, Xiang Y, Liu N, et al. The diagnostic value of PET/CT combined with HRCT in the aggressiveness of pulmonary solitary ground glass nodules[J]. J Pract Radiol, 2020, 36(5): 722−726. DOI: 10.3969/j.issn.1002-1671.2020.05.009.[16] 董科, 舒锦尔, 王利霞, 等. 不同病理阶段肺腺癌性磨玻璃结节PET/CT表现差异分析[J]. 中国临床医学影像杂志, 2017, 28(11): 793−797. DOI: 10.3969/j.issn.1008-1062.2017.11.008.
Dong K, Shu JE, Wang LX, et al. Different PET/CT diagnosis and pathologicaltypes of lung adenocarcinoma presenting as isolated ground-glass nodules[J]. J China Clin Med Imaging, 2017, 28(11): 793−797. DOI: 10.3969/j.issn.1008-1062.2017.11.008.[17] Chiu CH, Yeh YC, Lin KH, et al. Histological subtypes of lung adenocarcinoma have differential 18F-fluorodeoxyglucose uptakes on the positron emission tomography/computed tomography scan[J]. J Thorac Oncol, 2011, 6(10): 1697−1703. DOI: 10.1097/JTO.0b013e318226b677. [18] Li Y, Wu XD, Huang Y, et al. 18F-FDG PET/CT in lung adenosquamous carcinoma and its correlation with clinicopathological features and prognosis[J]. Ann Nucl Med, 2020, 34(5): 314−321. DOI: 10.1007/s12149-020-01450-1. [19] Lee Y, Chung JH, Kim SE, et al. Adenosquamous carcinoma of the lung: CT, FDG PET, and clinicopathologic findings[J]. Clin Nucl Med, 2014, 39(2): 107−112. DOI: 10.1097/RLU.0b013e3182952c2d. [20] Bianconi F, Palumbo I, Fravolini ML, et al. Texture analysis on [18F]FDG PET/CT in non-small-cell lung cancer: correlations between PET features, CT features, and histological types[J]. Mol Imaging Biol, 2019, 21(6): 1200−1209. DOI: 10.1007/s11307-019-01336-3. [21] Ha S, Choi H, Cheon GJ, et al. Autoclustering of non-small cell lung carcinoma subtypes on 18F-FDG PET using texture analysis: a preliminary result[J]. Nucl Med Mol Imaging, 2014, 48(4): 278−286. DOI: 10.1007/s13139-014-0283-3. [22] Kirienko M, Cozzi L, Rossi A, et al. Ability of FDG PET and CT radiomics features to differentiate between primary and metastatic lung lesions[J]. Eur J Nucl Med Mol Imaging, 2018, 45(10): 1649−1660. DOI: 10.1007/s00259-018-3987-2. [23] Tomori Y, Yamashiro T, Tomita H, et al. CT radiomics analysis of lung cancers: differentiation of squamous cell carcinoma from adenocarcinoma, a correlative study with FDG uptake[J]. Eur J Radiol, 2020, 128: 109032. DOI: 10.1016/j.ejrad.2020.109032. [24] Hyun SH, Ahn MS, Koh YW, et al. A machine-learning approach using PET-based radiomics to predict the histological subtypes of lung cancer[J]. Clin Nucl Med, 2019, 44(12): 956−960. DOI: 10.1097/RLU.0000000000002810. [25] Koyasu S, Nishio M, Isoda H, et al. Usefulness of gradient tree boosting for predicting histological subtype and EGFR mutation status of non-small cell lung cancer on 18F FDG-PET/CT[J]. Ann Nucl Med, 2020, 34(1): 49−57. DOI: 10.1007/s12149-019-01414-0.
计量
- 文章访问数: 5897
- HTML全文浏览量: 4436
- PDF下载量: 30